Full Text Journal Articles by
Author Waheed Jamal

Advertisement

Find full text journal articles








Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial.

Stefan D Anker, Javed Butler, Gerasimos Filippatos, Muhammad Shahzeb Khan, Nikolaus Marx, Carolyn S P Lam, Sven Schnaidt, Anne Pernille Ofstad, Martina Brueckmann, Waheed Jamal, Edimar Bocchi, Piotr Ponikowski, Sergio V Perrone, James L Januzzi, Subodh Verma, Michael Böhm, João Pedro Ferreira, Stuart J Pocock, Faiez Zannad, Milton Packer, ,

Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve outcomes in patients with heart failure with reduced ejection fraction, but additional information is needed about whether glycemic status influences the magnitude of their benefits on heart failure and renal events. Methods: Patients with class II-IV heart failure and a left ventricular ejection ... Read more >>

Circulation (Circulation)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.

Darren K McGuire, Bernard Zinman, Silvio E Inzucchi, Christoph Wanner, David Fitchett, Stefan D Anker, Stuart Pocock, Stefan Kaspers, Jyothis T George, Maximilian von Eynatten, Odd Erik Johansen, Waheed Jamal, Michaela Mattheus, Ulrich Elsasser, Stefan Hantel, Søren S Lund,

BACKGROUND:Patients with type 2 diabetes and atherosclerotic cardiovascular disease are at high clinical risk. We assessed the effect of the sodium-glucose co-transporter-2 inhibitor, empagliflozin, on total cardiovascular events and admissions to hospital in the EMPA-REG OUTCOME trial. METHODS:The EMPA-REG OUTCOME trial was a randomised, double-blind, non-inferiority trial of patients (aged ... Read more >>

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(12):949-959]

Cited: 0 times

View full text PDF listing >>



Advertisement

Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.

Milton Packer, Stefan D Anker, Javed Butler, Gerasimos S Filippatos, João Pedro Ferreira, Stuart Pocock, Peter E Carson, Inder S Anand, Wolfram Doehner, Markus Haass, Michel Komajda, Alan B Miller, Steen Pehrson, John R Teerlink, Martina Brueckmann, Waheed Jamal, Cordula Zeller, Sven Schnaidt, Faiez Zannad, ,

Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, with or without diabetes, but additional data are needed about the effect of the drug on inpatient and outpatient events that reflect worsening heart failure. Methods: We ... Read more >>

Circulation (Circulation)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Design of a Prospective Patient-Level Pooled Analysis of Two Parallel Trials of Empagliflozin in Patients With Established Heart Failure.

Milton Packer, Javed Butler, Gerasimos Filippatos, Faiez Zannad, Joao Pedro Ferreira, Cordula Zeller, Martina Brueckmann, Waheed Jamal, Stuart Pocock, Stefan D Anker, ,

The EMPEROR-Reduced trial demonstrated that empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with a reduced ejection fraction, and the EMPEROR-Preserved trial is currently evaluating the effect of the drug on the same endpoint in patients with an ejection fraction > 40%. However, neither ... Read more >>

Eur J Heart Fail (European journal of heart failure)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial.

Stefan D Anker, Javed Butler, Gerasimos Filippatos, Muhammad Shahzeb Khan, João Pedro Ferreira, Edimar Bocchi, Michael Böhm, Hans Pieter Brunner-La Rocca, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure, Nadia Giannetti, Juan Esteban Gomez-Mesa, Stefan Janssens, James L Januzzi, Jose R Gonzalez-Juanatey, Bela Merkely, Stephen J Nicholls, Sergio V Perrone, Ileana L Piña, Piotr Ponikowski, Michele Senni, Marie-France Seronde, David Sim, Jindrich Spinar, Iain Squire, Stefano Taddei, Hiroyuki Tsutsui, Subodh Verma, Dragos Vinereanu, Jian Zhang, Waheed Jamal, Sven Schnaidt, Janet M Schnee, Martina Brueckmann, Stuart J Pocock, Faiez Zannad, Milton Packer, ,

<b>Background: </b>EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares it with patients enrolled in prior HFpEF trials.<br><br><b>Methods: </b>EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, ... Read more >>

Eur J Heart Fail (European journal of heart failure)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann, Waheed Jamal, Karen Kimura, Janet Schnee, Cordula Zeller, Daniel Cotton, Edimar Bocchi, Michael Böhm, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure, Nadia Giannetti, Stefan Janssens, Jian Zhang, Jose R Gonzalez Juanatey, Sanjay Kaul, Hans-Peter Brunner-La Rocca, Bela Merkely, Stephen J Nicholls, Sergio Perrone, Ileana Pina, Piotr Ponikowski, Naveed Sattar, Michele Senni, Marie-France Seronde, Jindrich Spinar, Iain Squire, Stefano Taddei, Christoph Wanner, Faiez Zannad, ,

BACKGROUND:Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. ... Read more >>

N Engl J Med (The New England journal of medicine)
[2020, 383(15):1413-1424]

Cited: 4 times

View full text PDF listing >>



SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.

Faiez Zannad, João Pedro Ferreira, Stuart J Pocock, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Martina Brueckmann, Anne Pernille Ofstad, Egon Pfarr, Waheed Jamal, Milton Packer,

BACKGROUND:Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced (assessing empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) inhibition reduced the combined risk of cardiovascular death or hospitalisation for heart failure in patients with heart failure with reduced ejection fraction (HFrEF) with or without diabetes. However, neither trial was powered to assess effects on ... Read more >>

Lancet (Lancet (London, England))
[2020, 396(10254):819-829]

Cited: 1 time

View full text PDF listing >>



Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.

Stefan D Anker, Javed Butler, Gerasimos S Filippatos, Waheed Jamal, Afshin Salsali, Janet Schnee, Karen Kimura, Cordula Zeller, Jyothis George, Martina Brueckmann, Faiez Zannad, Milton Packer, ,

BACKGROUND:The principal biological processes that characterize heart failure with a preserved ejection fraction (HFpEF) are systemic inflammation, epicardial adipose tissue accumulation, coronary microcirculatory rarefaction, myocardial fibrosis and vascular stiffness; the resulting impairment of left ventricular and aortic distensibility (especially when accompanied by impaired glomerular function and sodium retention) causes increases ... Read more >>

Eur J Heart Fail (European journal of heart failure)
[2019, 21(10):1279-1287]

Cited: 8 times

View full text PDF listing >>



Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.

Milton Packer, Javed Butler, Gerasimos S Filippatos, Waheed Jamal, Afshin Salsali, Janet Schnee, Karen Kimura, Cordula Zeller, Jyothis George, Martina Brueckmann, Stefan D Anker, Faiez Zannad, ,

Drugs that inhibit the sodium-glucose co-transporter 2 (SGLT2) have been shown to reduce the risk of hospitalizations for heart failure in patients with type 2 diabetes. In populations that largely did not have heart failure at the time of enrolment, empagliflozin, canagliflozin and dapagliflozin decreased the risk of serious new-onset ... Read more >>

Eur J Heart Fail (European journal of heart failure)
[2019, 21(10):1270-1278]

Cited: 7 times

View full text PDF listing >>



Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.

William T Abraham, Piotr Ponikowski, Martina Brueckmann, Cordula Zeller, Hemani Macesic, Barbara Peil, Michèle Brun, Anastasia Ustyugova, Waheed Jamal, Afshin Salsali, JoAnn Lindenfeld, Stefan D Anker, ,

AIMS:Heart failure (HF) is associated with considerable symptom burden and impairment in physical functioning and quality of life. The sodium-glucose co-transporter 2 inhibitor empagliflozin reduced the risk of HF hospitalisation and cardiovascular death in patients with type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial, and could ... Read more >>

Eur J Heart Fail (European journal of heart failure)
[2019, 21(7):932-942]

Cited: 2 times

View full text PDF listing >>



A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.

Alexander G G Turpie, Sylvia Haas, Reinhold Kreutz, Lorenzo G Mantovani, Cassandra W Pattanayak, Gerlind Holberg, Waheed Jamal, André Schmidt, Martin van Eickels, Michael R Lassen,

Rivaroxaban demonstrated superior efficacy and a similar safety profile to enoxaparin for the prevention of venous thromboembolism in the phase III RECORD programme in patients undergoing elective hip or knee replacement surgery. The XAMOS study investigated adverse events, including bleeding and thromboembolic events, in patients receiving rivaroxaban for thromboprophylaxis in ... Read more >>

Thromb. Haemost. (Thrombosis and haemostasis)
[2014, 111(1):94-102]

Cited: 32 times

View full text PDF listing >>



Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery.

Alexander G G Turpie, André C Schmidt, Reinhold Kreutz, Michael R Lassen, Waheed Jamal, Lorenzo Mantovani, Sylvia Haas,

Venous thromboembolism is a frequent and potentially life-threatening complication of orthopedic surgery. Rivaroxaban is an oral direct factor Xa inhibitor, which was shown to be effective for the prevention of venous thromboembolism after elective hip and knee arthroplasty in the RECORD study program. Rivaroxaban has the potential to overcome the ... Read more >>

Vasc Health Risk Manag (Vascular health and risk management)
[2012, 8:363-370]

Cited: 9 times

View full text PDF listing >>



International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD).

Ajay K Kakkar, Iris Mueller, Jean-Pierre Bassand, David A Fitzmaurice, Samuel Z Goldhaber, Shinya Goto, Sylvia Haas, Werner Hacke, Gregory Y H Lip, Lorenzo G Mantovani, Freek W A Verheugt, Waheed Jamal, Frank Misselwitz, Sophie Rushton-Smith, Alexander G G Turpie,

BACKGROUND: Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling event. The ... Read more >>

Am. Heart J. (American heart journal)
[2012, 163(1):13-19.e1]

Cited: 77 times

View full text PDF listing >>



Application to vascular adventitia of a nonviral vector for TIMP-1 gene therapy to prevent intimal hyperplasia.

Qing-Hai Meng, Waheed Jamal, Stephen L Hart, Jean R McEwan,

Somatic gene transfer continues to have potential for the study and therapy of cardiovascular disease. We have developed a modular, self-assembling, nonviral system consisting of Lipofectin, integrin-targeting peptides, and plasmid DNA (LID) and we have applied this to a model of vascular injury, rat carotid angioplasty. Marker gene studies identified ... Read more >>

Hum. Gene Ther. (Human gene therapy)
[2006, 17(7):717-727]

Cited: 10 times

View full text PDF listing >>





Advertisement

Disclaimer
1.1469 s